About Latch Medical
Based in Dublin, Ireland, Latch Medical is a venture funded company with a platform microneedle technology. In summary, the technology is centred around opposing arrays of angled microneedles that can penetrate the outer layers of the skin in a manner ensuring consistent needle penetration and without the use of any adhesive. The platform can be utilised in a number of different applications, including drug delivery, biosensing, wearables and catheter securement. In 2019 our drug delivery technology – Pharma Latch was awarded a substantial grant by the Irish government. A rapid development plan ensued allowing the Pharma Latch technology progress and move forward.
Ronan Byrne MBA
A commercial specialist, Ronan has started, built and sold three companies over the course of his career. With a decade of experience in medical technologies, Ronan has both led and worked across a multitude of elements of medical technology innovation and commercial execution strategies. Ronan also works in a range of capacities with high potential medical technology companies in sectors ranging from ophthalmology through to cardiology. Ronan holds a BA degree (Economics & Politics) from UCD as well as an MBA Degree from UCD Smurfit Business School.
Dr Nicky Bertollo
A Biomedical Engineer with over 15 years’ experience in the design, development, preclinical testing and evaluation of medical devices. Nicky is the original inventor of the Latch platform tissue anchorage technology and a medical device innovator, with several medical device patents he has led having been licensed. He is a Fellow of the New South Wales Health Medical Device Commercialisation Training Program (Sydney, Australia) and holds BE (Mechanical), Masters (Biomedical Engineering) and PhD Degrees from the University of New South Wales (Sydney, Australia).
Dr Andrew Muddle
A transdermal and topical drug delivery expert, Dr Muddle was one of the Founders and CEO of MedPharm a UK based leading contract provider of topical and transdermal delivery solutions. This company was partially acquired in 2018 and Dr Muddle remains on the board. Dr. Muddle has spent over 30 years in the pharmaceutical industry in the drug delivery area and worked for a number of companies of varying sizes. At PowderJect Pharmaceuticals plc, he was Technical Director (Pharmaceutical Development) and was pivotal in the IPO in 1997. Prior to this he has also held technical positions with drug delivery companies such as the Elan Corporation, Ethical Pharmaceuticals Ltd (U.K.), Controlled Therapeutics (Scotland) and Ciba-Geigy (now Novartis).
Helen has over 25 years’ experience in the Medical Device Industry, including as Chief Executive Officer of Creganna Medical and Product Development and Research Roles at Medtronic and Covidien. She has a strong track record in scaling companies through acquisition and integration, strategic partnering and raising debt and equity financing. She acts as an advisor to Atlantic Bridge Ventures University Bridge Fund and currently serves as Director for Enterprise Ireland and a number of early-stage life sciences companies and charities. She is also Chair of the Implementation Group on Police Reform having recently served as a member of the Commission on the Future of Policing in Ireland.